Clinical trialPhase 3Recruiting
Safety and Efficacy of Immuncell-LC With Gemcitabine in Resectable Pancreatic Cancer
An Open-label, Randomized, Multi-center, Parallel, Phase III Clinical Trial to Evaluate the Efficacy and Safety of Adjuvant Immuncell-LC Therapy Combined With Gemcitabine Versus Adjuvant Gemcitabine Single Therapy After Resection in Patients With Pancreatic Ductal Adenocarcinoma
- Outcome
- Ongoing
- Phase
- Phase 3
- Status
- Recruiting
- Study type
- Interventional
- Start
- 7 September 2021
- Expected end
- June 2027
- Enrollment
- 408 participants
- Sites
- 1
- Primary outcomes
- Recurrence free survival (RFS) by independent review
- Sponsor
- Industry
- Results posted
- No
- Last update
- 22 November 2021
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
PURPOSE: This phase III clinical trial evaluates the efficacy and safety of adjuvant Immuncell-LC therapy combined with gemcitabine versus adjuvant gemcitabine single therapy after R0 or R1 resection in patients with pancreatic ductal adenocarcinoma.
Detailed description public domain (ClinicalTrials.gov)
Open-label, Randomized, Multi-center, Parallel, Phase III Clinical Trial